Methadone

Category
alkaloid
Half-Life (t½)
PO: 37h · IV: 37h
Formula
C21H27NO
Molecular Weight
309.45 g/mol
PubChem CID
4095

Pharmacological Mechanism

Synthetic μ-opioid agonist + NMDA antagonist + monoamine reuptake inhibition. Long, variable half-life (8–60 h) supports once-daily dosing for opioid use disorder. QT prolongation requires baseline ECG.

Half-Life & Elimination Curve (PO: 37h · IV: 37h)

100%50%25%12.5%0%0h0×t½37h1×t½3.1d2×t½4.6d3×t½6.2d4×t½7.7d5×t½0×t½ (0h): 100% remaining (~78.7 µg/L)1×t½ (37h): 50% remaining (~39.3 µg/L)2×t½ (3.1d): 25% remaining (~19.7 µg/L)3×t½ (4.6d): 12.5% remaining (~9.83 µg/L)4×t½ (6.2d): 6.3% remaining (~4.92 µg/L)5×t½ (7.7d): 3.1% remaining (~2.46 µg/L)
Plasma (PO)t½ Decay (37h)Effect Site (ke0)
  • 0×t½0h100% (78.7 µg/L)
  • 1×t½37h50% (39.3 µg/L)
  • 2×t½3.1d25% (19.7 µg/L)
  • 3×t½4.6d12.5% (9.83 µg/L)
  • 4×t½6.2d6.3% (4.92 µg/L)
  • 5×t½7.7d3.1% (2.46 µg/L)
Elimination t½37h (PO)
Rate Constant (ke)0.0187 h⁻¹
Time to Peak (Tmax)4.59h
Est. Peak (Cmax)78.7 µg/L
Clearance (CL)5.25 L/h
97% Washout (5×t½)7.7d

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References